Monashee Investment Management’s MoonLake Immunotherapeutics MLTX Stock Holding History

Monashee Investment Management’s Portfolio MLTX Stock Details MLTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-50,000	Closed	-$2.52M	–	74
2024 Q3	$2.52M	Hold	50,000	–	–	0.27%	54
2024 Q2	$2.2M	Sell	50,000 -65,000	-57%	-$2.75M	0.28%	39
2024 Q1	$5.78M	Buy	+115,000	New	+$6.24M	0.68%	23
2023 Q4	–	Sell	-50,000	Closed	-$2.85M	–	71
2023 Q3	$2.85M	Hold	50,000	–	–	1.19%	32
2023 Q2	$2.55M	Buy	+50,000	New	+$1.35M	0.61%	32
2022 Q4	–	Sell	-191,945	Closed	-$1.49M	–	57
2022 Q3	$1.49M	Sell	191,945 -8,055	-4%	-$56.9K	0.55%	30
2022 Q2	$1.05M	Buy	+200,000	New	+$1.26M	0.38%	19

Other funds holding MLTX

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Holocene Advisors New York $41.5B AUM 42.97% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return

Monashee Investment Management's MLTX Position: Q4 2024 in Review

Monashee Investment Management sold out of MoonLake Immunotherapeutics (MLTX) in Q4 2024, closing a stake of 50,000 shares — an estimated $2.52M sold.

Monashee Investment Management first reported a position in MLTX in Q2 2022 and held it in 7 quarters. The position peaked at $5.78M in Q1 2024. 115 funds tracked by Wall St. Rank hold MLTX as of Q4 2024.

Monashee Investment Management reported no remaining MoonLake Immunotherapeutics position as of Q4 2024 after selling out during the quarter.
Monashee Investment Management sold 50,000 MoonLake Immunotherapeutics shares in Q4 2024, an estimated $2.52M.
Monashee Investment Management first reported a position in MoonLake Immunotherapeutics in Q2 2022 and held it in 7 quarters.
Monashee Investment Management's MoonLake Immunotherapeutics position peaked at $5.78M in Q1 2024.
115 funds tracked by Wall St. Rank held MoonLake Immunotherapeutics as of Q4 2024.

Based on Monashee Investment Management's 13F filing for Q4 2024, filed 14 Feb 2025.